The global infectious bursal disease vaccine market is expected to grow with a CAGR of 5.2% from 2025 to 2031. The major drivers for this market are the rising poultry production and the outbreaks of infectious bursal disease.
The future of the global infectious bursal disease vaccine market looks promising with opportunities in the veterinary pharmacy and online sale markets.
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market, and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years, and what has its impact been on the industry?
The future of the global infectious bursal disease vaccine market looks promising with opportunities in the veterinary pharmacy and online sale markets.
- Within the type category, live is expected to witness higher growth over the forecast period due to rising demand for rapid and long-lasting immunity in poultry flocks, which is boosting the adoption of live vaccines.
- Within the application category, online sale is expected to witness higher growth due to rising demand for convenient procurement, which is driving poultry farmers to purchase IBD vaccines online, offering ease of access and timely delivery.
- In terms of region, North America is expected to witness the highest growth over the forecast period.
Emerging Trends in the Infectious Bursal Disease Vaccine Market
The infectious bursal disease vaccine market is evolving with several emerging trends that are shaping its future. As the poultry industry faces new challenges, these trends are influencing how vaccines are developed, distributed, and administered.- Increased Use of Combination Vaccines: The trend toward combination vaccines is gaining traction in the infectious bursal disease vaccine market, as farmers look for ways to protect against multiple diseases with a single vaccination. Combination vaccines that protect against IBD, Newcastle disease, and other viral infections are more cost-effective and reduce the number of vaccinations required. This trend is particularly significant in regions with limited access to veterinary services, where a single vaccine can offer broad-spectrum protection, thus improving overall animal health.
- Advancements in Vaccine Delivery Technologies: New vaccine delivery technologies, such as needle-free injection systems and oral vaccines, are gaining popularity in the poultry industry. These methods offer easier administration, reduce stress on animals, and eliminate the need for needles, which can increase the risk of injury. In addition, these delivery systems allow for faster and more efficient mass vaccination, improving the overall effectiveness of vaccination programs and reducing costs.
- Focus on Biosecurity and Disease Prevention: As biosecurity practices become a priority for poultry farms worldwide, there is an increasing emphasis on the prevention of IBD outbreaks through vaccination. This includes better management of poultry environments, improved hygiene, and the use of vaccines to ensure that flocks remain healthy. With IBD being highly contagious, vaccination is seen as a critical component of biosecurity programs aimed at minimizing disease transmission and ensuring the long-term sustainability of poultry farming.
- Regulatory and Safety Advancements: With growing concerns about vaccine safety and efficacy, regulatory agencies are implementing stricter standards for vaccine approval and monitoring. In response, vaccine manufacturers are investing in research and development to ensure that their products meet these higher standards. This includes improving the consistency and stability of vaccines, as well as ensuring that they provide long-term protection against emerging strains of IBD.
- Regional Vaccine Production and Local Strain Adaptation: To meet the demand for infectious bursal disease vaccines in diverse geographical regions, there is a growing focus on producing vaccines that are tailored to local strains of the virus. Regional vaccine production is becoming more common in countries like China and India, where local strains of IBD may vary from those found in other parts of the world. This trend is expected to increase vaccine efficacy, reduce costs, and improve the accessibility of vaccines in developing regions.
Recent Developments in the Infectious Bursal Disease Vaccine Market
Several key developments have taken place in the infectious bursal disease vaccine market, each contributing to improved control of the disease in poultry.- Advances in Recombinant DNA Vaccines: The development of recombinant DNA vaccines has revolutionized the infectious bursal disease vaccine market. These vaccines are more effective in preventing disease and offer enhanced safety profiles, as they are less likely to cause adverse reactions in poultry. Recombinant vaccines also provide broader protection against various strains of IBD, which is critical in regions where the virus may mutate rapidly.
- Improved Cold-Chain Distribution: Cold-chain distribution systems have been strengthened to ensure that infectious bursal disease vaccines remain effective during transportation and storage. With vaccines requiring strict temperature control, advancements in refrigeration and packaging technologies have enhanced the global reach of vaccines, particularly in rural and underserved areas. These improvements have helped reduce vaccine spoilage and ensure that vaccines reach their destination in optimal condition.
- Focus on Antibody Detection and Monitoring: Advances in diagnostic tools for detecting antibodies against IBD are enabling farmers to monitor vaccine effectiveness and determine the best times for vaccination. These tools help identify immune status in poultry, allowing for more targeted vaccination strategies. Early detection of IBD antibodies can also guide farmers in implementing additional biosecurity measures or boosting vaccination efforts to prevent outbreaks.
- Emergence of Custom-Formulated Vaccines: As the global poultry market grows, vaccine manufacturers are increasingly focusing on developing custom-formulated infectious bursal disease vaccines tailored to specific regional needs. These vaccines are designed to address local variations of the virus, ensuring higher efficacy and minimizing the risk of disease outbreaks in different geographical areas.
- Increase in Government Support and Funding: Governments around the world are providing more support and funding for vaccination programs to combat IBD outbreaks. This includes subsidies for purchasing vaccines, funding for research, and collaborations with global health organizations. This increased support has helped accelerate vaccine adoption and improve public confidence in the effectiveness of vaccination programs.
Strategic Growth Opportunities in the Infectious Bursal Disease Vaccine Market
The infectious bursal disease vaccine market offers significant growth opportunities across various applications, especially with the evolving demands of the poultry industry.- Growth in Developing Markets: The expansion of the poultry industry in developing countries such as India, China, and Southeast Asia presents significant growth opportunities. Vaccination programs are increasingly prioritized in these regions as farmers seek to improve poultry health and productivity. The expansion of local vaccine production and distribution networks will play a key role in meeting the growing demand.
- Introduction of Affordable Vaccines: The development of cost-effective infectious bursal disease vaccines is essential for expanding vaccination coverage in low-income regions. Vaccine manufacturers are exploring ways to reduce production costs without compromising quality. This includes scaling up production and improving the efficiency of vaccine delivery systems to make vaccines more affordable and accessible to smallholder farmers.
- Expansion of Veterinary Services: The expansion of veterinary services, particularly in rural areas, presents a growth opportunity for IBD vaccine manufacturers. Improved access to veterinary care and vaccination programs will boost vaccine uptake, reducing the incidence of IBD outbreaks. Investment in rural veterinary infrastructure and education is crucial to reaching underserved populations.
- Innovations in Vaccine Administration: Advances in vaccine delivery systems, such as needle-free injectors and oral vaccines, are creating new opportunities for market growth. These technologies offer significant advantages in terms of ease of use, safety, and cost-effectiveness, making it easier for farmers to vaccinate large flocks quickly and efficiently.
- Collaboration with Global Health Organizations: Collaborations with organizations such as the World Health Organization (WHO) and the Food and Agriculture Organization (FAO) will enhance the reach and effectiveness of IBD vaccination programs. These partnerships can provide funding, technical support, and expertise to improve vaccine distribution and increase awareness in regions with limited healthcare infrastructure.
Infectious Bursal Disease Vaccine Market Driver and Challenges
The infectious bursal disease vaccine market is driven by several factors but also faces several challenges that could impact its growth.The factors responsible for driving the infectious bursal disease vaccine market include:
- Technological advancements: Advances in vaccine technology, including recombinant vaccines and viral vector-based vaccines, are driving market growth. These innovations are making vaccines more effective and safer for poultry, leading to higher adoption rates.
- Increasing poultry demand: Rising demand for poultry products worldwide, particularly in developing countries, is driving the need for more efficient disease prevention methods. Infectious bursal disease vaccines play a crucial role in maintaining healthy poultry stocks and ensuring food security.
- Government support and regulations: Government initiatives, subsidies, and regulations to control poultry diseases are driving the adoption of infectious bursal disease vaccines. The implementation of stricter animal health standards and biosecurity measures is pushing for widespread vaccination.
- Focus on animal health: As consumers demand safer and healthier poultry products, the focus on animal health is intensifying. Vaccines are seen as a critical tool in preventing IBD outbreaks and ensuring the overall health of poultry.
- Globalization of poultry trade: As poultry trade expands globally, ensuring the health of poultry is crucial for avoiding disease outbreaks and maintaining trade relations. This has led to greater investments in vaccination programs and better disease surveillance.
Challenges in the infectious bursal disease vaccine market are:
- Vaccine distribution issues: One of the major challenges in the infectious bursal disease vaccine market is ensuring the efficient and timely distribution of vaccines, particularly in rural and remote areas. Cold-chain logistics and vaccine storage issues often impede vaccine availability.
- Vaccine resistance and mutation: The ability of the IBD virus to mutate over time poses a challenge for vaccine efficacy. Manufacturers must continually adapt vaccines to address new strains of the virus, which increases R&D costs and complexity.
- Vaccine hesitancy: In some regions, there is a reluctance among farmers to adopt vaccination programs due to a lack of awareness, perceived costs, or mistrust in the vaccine's effectiveness. Addressing vaccine hesitancy remains a critical challenge for the industry.
List of Infectious Bursal Disease Vaccine Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leveraging integration opportunities across the value chain. With these strategies, infectious bursal disease vaccine companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the infectious bursal disease vaccine companies profiled in this report include:
- Zoetis
- Merck
- Elanco
- Boehringer Ingelheim
- Ceva
- Qingdao Yibang Biological Engineering
Infectious Bursal Disease Vaccine Market by Segment
The study includes a forecast for the global infectious bursal disease vaccine market by type, application, and region.Type [Value from 2019 to 2031]:
- Live
- Inactivated
Application [Value from 2019 to 2031]:
- Veterinary Pharmacy
- Online Sale
- Others
Region [Value from 2019 to 2031]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country-wise Outlook for the Infectious Bursal Disease Vaccine Market
The global infectious bursal disease vaccine market has seen significant developments in recent years, driven by increasing demand for poultry vaccines, growing awareness about animal health, and advancements in vaccine technology. IBD, a highly contagious viral disease in chickens, has spurred continuous innovation in the development of effective vaccines. This is particularly evident in the United States, China, Germany, India, and Japan, where the poultry industry plays a vital role in food security and economic stability. As vaccination programs expand and evolve, these countries have experienced various developments in the infectious bursal disease vaccine market.- United States: In the United States, the infectious bursal disease vaccine market has experienced steady growth, driven by advancements in vaccine formulation and delivery methods. The adoption of recombinant DNA technology and inactivated vaccines has improved the effectiveness of vaccines against IBD, with a focus on reducing the use of antibiotics in poultry farming. Efforts to combat antimicrobial resistance have resulted in increased demand for vaccines that promote healthy poultry without the need for extensive antibiotic treatments. Additionally, U.S. poultry farmers are increasingly adopting biosecurity measures, including vaccination programs, to reduce the risk of disease outbreaks.
- China: China has emerged as one of the largest markets for infectious bursal disease vaccines due to its massive poultry industry, which is crucial for the country’s food security. Recent developments in China focus on enhancing the efficacy and safety of infectious bursal disease vaccines, with a particular emphasis on improving the cold-chain distribution system. Chinese companies are increasingly developing locally produced vaccines to meet the growing demand, which has been further fueled by outbreaks of IBD in poultry farms. Furthermore, China has implemented stronger regulations and monitoring systems to ensure the quality and safety of vaccines, bolstering public confidence.
- Germany: Germany, as a leader in the European poultry industry, has been at the forefront of innovations in the infectious bursal disease vaccine market. With strict regulations on animal health and biosecurity, Germany has been a pioneer in the development of advanced vaccine technologies, including the use of viral vector-based vaccines. German poultry farmers are increasingly adopting vaccines that are designed to provide broader protection against various strains of IBD. In addition, German veterinary associations have been actively promoting the importance of vaccination as part of comprehensive animal health programs to prevent outbreaks and improve poultry productivity.
- India: In India, the infectious bursal disease vaccine market is witnessing rapid growth due to the expanding poultry industry and increasing awareness of the importance of vaccination in preventing infectious diseases. With rising demand for poultry products, Indian poultry farmers are adopting more advanced and cost-effective vaccines. The government and private sector are working together to expand vaccination coverage and strengthen the veterinary infrastructure in rural areas. Efforts to develop vaccines tailored to local strains of IBD and improve distribution systems are helping address the challenges faced by the Indian poultry sector.
- Japan: Japan’s poultry industry has experienced steady progress in controlling IBD outbreaks through widespread vaccination programs. The focus on high-quality vaccines, such as live attenuated and inactivated vaccines, has helped improve the health and productivity of poultry farms. Japanese farmers are increasingly utilizing vaccination as a proactive measure to prevent disease outbreaks, with an emphasis on early vaccination during the critical stages of poultry development. Additionally, Japan has been working to improve the surveillance of poultry diseases and strengthen its regulatory frameworks, ensuring that vaccines are safe and effective.
Features of this Global Infectious Bursal Disease Vaccine Market Report
- Market Size Estimates: Infectious bursal disease vaccine market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
- Segmentation Analysis: Infectious bursal disease vaccine market size by type, application, and region in terms of value ($B).
- Regional Analysis: Infectious bursal disease vaccine market breakdown by North America, Europe, Asia Pacific, and the Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the infectious bursal disease vaccine market.
- Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the infectious bursal disease vaccine market.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the infectious bursal disease vaccine market by type (live and inactivated), application (veterinary pharmacy, online sale, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market, and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years, and what has its impact been on the industry?
Table of Contents
1. Executive Summary
2. Market Overview
3. Market Trends & Forecast Analysis
4. Global Infectious Bursal Disease Vaccine Market by Type
5. Global Infectious Bursal Disease Vaccine Market by Application
6. Regional Analysis
7. North American Infectious Bursal Disease Vaccine Market
8. European Infectious Bursal Disease Vaccine Market
9. APAC Infectious Bursal Disease Vaccine Market
10. RoW Infectious Bursal Disease Vaccine Market
11. Competitor Analysis
12. Opportunities & Strategic Analysis
13. Company Profiles of the Leading Players Across the Value Chain
14. Appendix
List of Figures
List of Tables
Companies Mentioned
The major companies profiled in this Infectious Bursal Disease Vaccine market report include:- Zoetis
- Merck
- Elanco
- Boehringer Ingelheim
- Ceva
- Qingdao Yibang Biological Engineering
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.
LOADING...
